アジェンダ
7:00 AM — 8:00 AM
8:00 AM — 8:30 AM
Welcome Remarks and Overview of the 2017 Conference10:30 AM — 11:00 AM
11:00 AM — 12:30 PM
Session 2A: Control Strategy for Double-Stranded Oligonucleotides11:00 AM — 12:30 PM
Session 2B: Assessing the Implications of Oligonucleotide Uptake into Cells11:00 AM — 12:30 PM
Session 2C: Cardiovascular/Metabolic Diseases12:30 PM — 1:30 PM
3:00 PM — 3:30 PM
5:00 PM — 6:00 PM
Poster Session and Networking Reception8:00 AM — 9:00 AM
9:00 AM — 9:05 AM
Welcome to Day Two9:05 AM — 10:05 AM
Session 5: Keynote Address10:05 AM — 10:30 AM
10:30 AM — 12:00 PM
Session 6A: Thinking Ahead: Oligonucleotide Drug-Device Combination Products12:00 PM — 1:30 PM
1:30 PM — 3:00 PM
Session 7A: Recently Approved and Late-Stage Oligonucleotide Drugs3:00 PM — 3:30 PM
5:00 PM — 5:30 PM
DIA Oligonucleotide Safety Working Group (OSWG) – Open Meeting7:00 AM — 8:00 AM
8:00 AM — 9:30 AM
Session 9A: Interactive Discussion of CMC Challenges and Moving Forward8:00 AM — 9:30 AM
Session 9BC: Expanding Therapeutic Utility via Targeted Delivery9:30 AM — 9:45 AM
9:45 AM — 11:15 AM
Session 10: Hot Topics in Oligonucleotide Therapeutics11:15 AM — 12:00 PM
Closing Session: Panel Discussion